2022 / Retrospective Cohort / Strong evidenceLegalization cut adult cannabis possession arrests by 40-76%, even in states that already decriminalized, but did not change youth arrest rates or racial disparities.
2022 / Retrospective Cohort / Moderate evidenceColorado county-level analysis found dispensary openings increased cannabis-related hospitalizations but not traffic crash rates.
2022 / Retrospective Cohort / Strong evidenceCannabis decriminalization in 11 states cut arrests 70% for adults, 40% for youth, and reduced Black-White adult arrest disparity by 17%.
2022 / Narrative Review / Moderate evidenceTHC modulates reward-related brain regions in ways that correlate with psychotic symptoms. CBD appears to act in the opposite direction on the same regions.
2022 / Meta Analysis / Strong evidenceMeta-analysis of 372 participants found THC's brain effects are dose-dependent and track with CB1 receptor density across regions.
2022 / Qualitative / Preliminary evidencePediatric clinicians in Canada support medical cannabis under harm reduction principles but face authorization barriers and want more neurodevelopmental research.
2022 / Review / Preliminary evidenceTopical CBD may promote hair growth at low concentrations but cause loss at high concentrations. One trial saw a 93.5% increase in hair count over 6 months.
2022 / Prospective Cohort / Preliminary evidenceIn 28 chronic pain patients, three months of medical cannabis produced no significant changes in blood sugar, cholesterol, insulin, cortisol, or body weight.
2022 / Cross Sectional / Preliminary evidenceAmong 70 Canadian healthcare providers, 56% felt uncomfortable with their cannabis knowledge, and uncertainty about dosing was the top barrier to prescribing.
2022 / Pilot Study / Moderate evidence82 children with autism who completed 6 months of CBD-rich cannabis showed significant improvements in social communication on both clinical and parent-reported measures.
2022 / Review / Moderate evidenceCannabis-based treatments, especially nabiximols spray and oral cannabinoids, consistently helped with MS pain and spasticity but showed only slight improvement for other MS symptoms.
2022 / Meta Analysis / Strong evidenceMeta-analysis of 45 fMRI studies (2,702 youth) found cannabis users showed altered activation in prefrontal and cingulate regions, varying by sex, severity, and psychiatric comorbidity.
2022 / Randomized Controlled Trial / Moderate evidenceIn 15 daily cannabis smokers, the COX-2 inhibitor celecoxib did not reduce withdrawal symptoms or change endocannabinoid levels, and it increased cannabis craving.
2022 / Retrospective Cohort / Moderate evidenceAmong 422 pediatric ER patients testing positive for cannabis, 71% presented after legalization. Suicidal ideation was the most common complaint at 43%.
2022 / Narrative Review / Preliminary evidenceEmployers face conflicting laws and unreliable drug tests — a practical framework for cannabis workplace policies addresses safety, legal protections, and impairment measurement.
2022 / Animal Study / Moderate evidenceSix rhesus macaques given daily THC edibles experienced 58% testicular volume loss and hormone shifts consistent with testicular failure, in a dose-dependent pattern.
2022 / Narrative Review / Preliminary evidenceReview argues antidepressants are likely less effective in cannabis-using teens, based on overlapping neurochemical pathways, but no clinical trials have tested this directly.
2022 / Animal Study / Moderate evidenceBlocking CB1 receptor desensitization delayed THC tolerance in male mice but not females, revealing sex-specific mechanisms. Females were also less sensitive to cannabinoid pain relief.
2022 / Case Report / Preliminary evidenceFirst case of pneumorrhachis (spinal air leak) linked to cannabinoid hyperemesis syndrome, caused by severe, repeated vomiting.
2022 / Review / Preliminary evidencePeople with ADHD may use cannabis to manage self-regulation deficits, but evidence for therapeutic benefit is limited and the risk of problematic use is elevated.
2022 / Cross Sectional / Strong evidenceAmong 608 US veterans with PTSD, frequent cannabis users were 3-4x more likely to have depression, anxiety, and suicidal ideation, and 8-12x more likely to rely on avoidance coping.
2022 / Observational / Moderate evidenceMultimodal brain imaging of 24 heavy cannabis users found distinct structural and functional changes linked to serotonin, dopamine, and opioid receptor systems.
2022 / Review / Moderate evidenceStandard ASD medications often cause side effects that mimic ASD symptoms. Early evidence suggests CBD-rich cannabis may be effective and better tolerated, but controlled trials are needed.
2022 / Cross Sectional / Moderate evidenceAmong 9,863 US adolescents, racial bullying involvement predicted different substance use patterns by ethnicity, with African American bully-victims more likely to use marijuana.
2022 / Cross Sectional / Moderate evidenceAnalysis of 1,174 young adults found five distinct cannabis use disorder profiles with different patterns of consumption, control, and withdrawal symptoms.
2022 / Randomized Controlled Trial / Strong evidenceCannabis with equal THC and CBD caused less anxiety than THC alone. CBD fully blocked THC anxiety in calm users but not in those with high baseline anxiety.
2022 / Cross Sectional / Moderate evidenceAmong 910 young Canadian adults who drive after cannabis use, four distinct profiles emerged, from well-adjusted youth to those with generalized risky behavior and high distress.
2022 / Observational / Moderate evidenceSchizophrenia patients with cannabis use disorder showed different blood biomarker patterns than those with schizophrenia alone, with elevated serotonin receptors and inflammation markers absent in dual-diagnosis patients.
2022 / Animal Study / Moderate evidenceMouse pups exposed to CBD prenatally showed sex-specific disruptions: males gained extra weight and changed vocalizations, while females had impaired motor and discrimination abilities.
2022 / Review / Strong evidenceAnimal studies consistently show prenatal cannabis/THC exposure causes cognitive, emotional, and drug sensitivity changes in offspring, supporting their classification as developmental toxicants.
2022 / Retrospective Cohort / Strong evidenceAmong 3.3 million cannabis hospitalizations, pulmonary circulation disorders increased 200% over 7 years, with patients facing 2x the in-hospital mortality risk.
2022 / Narrative Review / Moderate evidenceCannabinoids show some pain benefits for rheumatic conditions but carry drug interaction risks with common rheumatology medications, leading the review to conclude they are more foe than friend.
2022 / Narrative Review / Preliminary evidenceCannabinoids including CBD and CBGA have anti-inflammatory and antiviral properties that could theoretically help with COVID-19, but no clinical evidence exists.
2022 / Observational / Strong evidenceIn 71 patients, blood levels of the synthetic cannabinoid 5F-MDMB-PICA followed a dose-response pattern with CB1 receptor activation, and higher activation predicted greater loss of consciousness.
2022 / Longitudinal Cohort / Strong evidenceAmong 4,270 French students, ADHD symptoms predicted continued cannabis use after one year but did not drive new cannabis initiation.
2022 / Animal Study / Moderate evidenceIn a schizophrenia rat model, THC-only cannabis vapor worsened brain oscillation deficits while balanced THC/CBD vapor preserved or enhanced brain activity.
2022 / Animal Study / Moderate evidenceIn rats with nerve injury pain, CBD enhanced morphine's effectiveness at sub-therapeutic doses and partially prevented morphine tolerance development.
2022 / Cross Sectional / Moderate evidenceChildren of caregivers who smoked marijuana had 26% more viral respiratory infections per year compared to unexposed children in a survey of 1,500 families.
2022 / Observational / Strong evidenceLab testing found THC in 65% of 80 CBD products, including 24% of those labeled "THC-Free," with concentrations up to 2 mg/mL.
2022 / Observational / Strong evidenceNearly half of 80 CBD products tested had CBD concentrations more than 10% off their labels, with some containing less than half the advertised amount.
2022 / Retrospective Cohort / Strong evidenceAmong 1,540 newborns with meconium drug testing, THC-exposed infants weighed 0.16 kg less and had 1.9x the odds of low birth weight.
2022 / Review / Moderate evidenceMarijuana causes bronchitis but the evidence suggests it does not cause COPD and probably does not cause lung cancer, a distinctly different pattern from tobacco.
2022 / Cross Sectional / Strong evidenceNational data from 2011-2017 found marijuana associated with teen suicidal ideation and attempts at rates comparable to tobacco and alcohol, with a dose-response pattern.
2022 / Animal Study / Moderate evidenceIn rats, CBD reduced risperidone-induced blood sugar elevation, movement abnormalities, and muscle stiffness without impairing cognition.
2022 / Observational / Moderate evidenceFrequent cannabis users showed peak psychomotor impairment immediately after smoking but recovered significantly within one hour, replicated across two studies.
2022 / Retrospective Cohort / Moderate evidenceIn Lebanon, cannabis use disorder nearly tripled the odds of needing intensive psychiatric outreach for psychosis, alongside other severity markers.
2022 / Cross Sectional / Moderate evidenceCannabis use was linked to suicidal ideation in 412 youth aged 13-18, but existing school prevention policies did not weaken this association.
2022 / Longitudinal Cohort / Moderate evidenceAmong 835 high schoolers, buying cannabis from someone or using a medical card at a dispensary predicted continued and more frequent use six months later.
2022 / Narrative Review / Preliminary evidenceCBD and THC do not boost athletic performance. CBD's anti-inflammatory potential remains untested in sport. Some CBD products may trigger positive drug tests due to THC contamination.
2022 / Animal Study / Moderate evidenceTHC withdrawal in mice disrupted dopamine release, sleep patterns, and behavior in ways that mirror human withdrawal, with more pronounced effects in males.